Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indinavir and Ritonavir in PI-Experienced HIV
NCT00002361Phase 2Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indinavir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Proportion of patients achieving plasma viral RNA levels below 50 copies/ml at 24 weeks and Incidence of serious and drug-related adverse experiences at 24 weeks. Status: completed.
02
Drugs
indinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002361.